Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1K23HL078760-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Insufficient recruitment to meet aims.
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine if treating delirious intensive care unit patients with haloperidol improves mortality.
Intensive care unit delirium is a serious medical condition that is associated with increased morbidity and mortality. In this study, 304 delirious mechanically ventilated subjects will be randomized to haloperidol 5mg IV every 12 hours or placebo to determine if treatment with haloperidol improves short and long-term mortality.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| haloperidol | Experimental | Once diagnosed as delirious, randomized to haloperidol 5 mg IV |
|
| placebo | Placebo Comparator | once diagnosed as delirious, received 5 mg saline placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| haloperidol | Drug | Aim #1. To conduct a RCT of IV haloperidol vs. placebo for the treatment of delirium in mechanically ventilated ICU patients. Patients in the cohort study that go on to develop delirium will be enrolled in a RCT comparing treatment with scheduled haloperidol vs. placebo. By comparing differences between treatment and placebo groups, we will test the hypothesis that treatment with scheduled haloperidol improves the primary outcome of 28-day and 90 day mortality and secondary outcomes of total delirium days, duration of mechanical ventilation, and ICU length of stay. |
| Measure | Description | Time Frame |
|---|---|---|
| 28-day All-cause Mortality | Daily | |
| 90-day All-cause Mortality | 90 Days from enrollment in study |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of Mechanical Ventilation | daily | |
| ICU Length of Stay | Daily |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Eric B Milbrandt, MD, MPH | University of Pittsburgh Medical Center | Principal Investigator |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 15644675 | Background | Milbrandt EB, Kersten A, Kong L, Weissfeld LA, Clermont G, Fink MP, Angus DC. Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. Crit Care Med. 2005 Jan;33(1):226-9; discussion 263-5. doi: 10.1097/01.ccm.0000150743.16005.9a. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
7 of 40 enrolled subjects never developed delirium, while 2 of 40 had persistent coma and died without ever opening eyes. Subjects were randomized to groups once the delirium was diagnosed. 31 subjects developed delirium and were eligible to randomized. 1 withdrew before starting/being randomized, as a result, 30 subjects were randomized.
This study was pre-maturely terminated and although sincere efforts were made to locate the relevant (and accurate) data for results reporting, limited data could be obtained and are reported in the Results section. Some data were either missing or were conflicting and were therefore, excluded.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Haloperidol | Once delirium was diagnosed, subjects were randomized to haloperidol 5 mg IV q 12h, which was continued until liberation from mechanical ventilation or 28 days, whichever was first. |
| FG001 | Placebo | Once delirium was diagnosed, subjects were randomized to identical placebo, which was continued until liberation from mechanical ventilation or 28 days, whichever was first. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Haloperidol | Once delirium was diagnosed, subjects were randomized to haloperidol 5 mg IV q 12h, which was continued until liberation from mechanical ventilation or 28 days, whichever was first. |
| BG001 | Placebo |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | 28-day All-cause Mortality | This study was pre-maturely terminated and although sincere efforts were made to locate the relevant and accurate data for results reporting, limited data could be obtained. Data are not available per-Arm (Haloperidol vs Placebo) for this Outcome Measure. The only available data are grouped by the "Delirium," "Persistent Coma," and "No delirium". | Posted | Count of Participants | Participants | Daily |
|
Limited data can be obtained to make sure AE data time frame. However, once the patient has left the ICU, data will no longer collect on a daily basis. On or about day 28 after enrollment and 90-days after enrollment, a research coordinator will contact the patient. For this 28-day and 90-day follow-up, the following were recorded 1) whether the patient is in the hospital and if not, where the patient was discharged to, and 2) if the patient is alive and if not, what the cause of death was.
All the AEs were reported as the relationship to study drug. The following four cases were reported as very likely related to study drug. AEs were not reported as "Serious" or not in the limited data we found. All the AEs were listed in one table, and only Elevated QTc 494, 505, 548, 520 are very likely related to study drug, and the others are not related to study drug.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Haloperidol | Once delirium was diagnosed, subjects were randomized to haloperidol 5 mg IV q 12h, which was continued until liberation from mechanical ventilation or 28 days, whichever was first. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Elevated QTc .494 | Cardiac disorders |
This study was pre-maturely terminated. Although sincere efforts were made to locate the relevant and accurate data, limited data could be obtained. Also, conflicting information was available with respect to participant enrollment.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Barb Early, RN, BSN, CCRC | UPittsburgh | (412) 647-9745 | earlybj@upmc.edu |
| ID | Term |
|---|---|
| D003693 | Delirium |
| ID | Term |
|---|---|
| D003221 | Confusion |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D006220 | Haloperidol |
| ID | Term |
|---|---|
| D002090 | Butyrophenones |
| D007659 | Ketones |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Saline placebo | Other | control arem |
|
Once delirium was diagnosed, subjects were randomized to identical placebo, which was continued until liberation from mechanical ventilation or 28 days, whichever was first.
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| OG001 | Persistent Coma |
| OG002 | No Delirium |
|
|
| Primary | 90-day All-cause Mortality | This study was pre-maturely terminated and although sincere efforts were made to locate the relevant and accurate data for results reporting, limited data could be obtained. Data are not available per-Arm (Haloperidol vs Placebo) for this Outcome Measure. The only available data are grouped by the "Delirium," "Persistent Coma," and "No delirium". | Posted | Count of Participants | Participants | 90 Days from enrollment in study |
|
|
|
| Secondary | Duration of Mechanical Ventilation | This study was pre-maturely terminated and although sincere efforts were made to locate the relevant and accurate data for results reporting, limited data could be obtained. Data are not available per-Arm (Haloperidol vs Placebo) for this Outcome Measure. The only available data are grouped by the "Delirium," "Persistent Coma," and "No delirium". | Posted | Median | Inter-Quartile Range | day | daily |
|
|
|
| Secondary | ICU Length of Stay | This study was pre-maturely terminated and although sincere efforts were made to locate the relevant and accurate data for results reporting, limited data could be obtained. Data are not available per-Arm (Haloperidol vs Placebo) for this Outcome Measure. The only available data are grouped by the "Delirium," "Persistent Coma," and "No delirium". | Posted | Median | Inter-Quartile Range | day | Daily |
|
|
|
| 1 |
| 16 |
| 0 |
| 16 |
| 16 |
| 16 |
| EG001 | Placebo | Once delirium was diagnosed, subjects were randomized to identical placebo, which was continued until liberation from mechanical ventilation or 28 days, whichever was first. | 2 | 13 | 0 | 13 | 12 | 13 |
| Elevated QTc .505 | Cardiac disorders |
|
| Elevated QTc 548 | Cardiac disorders |
|
| Elevated QTc 520 | Cardiac disorders |
|
| Hypoxemic resp failure ARDS | Respiratory, thoracic and mediastinal disorders |
|
| Cellulitis | Infections and infestations |
|
| Nosocomial pneumonia | Respiratory, thoracic and mediastinal disorders |
|
| RUL collapse | Respiratory, thoracic and mediastinal disorders |
|
| Bilateral infiltrates | Respiratory, thoracic and mediastinal disorders |
|
| Trachestomy | Respiratory, thoracic and mediastinal disorders |
|
| Abdominal surgery (closure) | Surgical and medical procedures |
|
| Intrapulmonary hemorrhage | Respiratory, thoracic and mediastinal disorders |
|
| Tachycardia, restlessness desat | Respiratory, thoracic and mediastinal disorders |
|
| OR-cleansing and closure of leg wound | Surgical and medical procedures |
|
| Lower lobectomy | Respiratory, thoracic and mediastinal disorders |
|
| Self extubation with continued resp. insufficiency | Respiratory, thoracic and mediastinal disorders |
|
| GU hemorrhage related to selfremoval of Foley catheter | Gastrointestinal disorders |
|
| Reintubated for resp. insufficiency | Respiratory, thoracic and mediastinal disorders |
|
| Failure to wean from ventilator | Respiratory, thoracic and mediastinal disorders |
|
| Pseudomonas pneumonia | Respiratory, thoracic and mediastinal disorders |
|
| MRSA | Infections and infestations |
|
| ARF | Renal and urinary disorders |
|
| VTach | Cardiac disorders |
|
| Hypertension | Vascular disorders |
|
| Viral pneumonia, ARDS | Respiratory, thoracic and mediastinal disorders |
|
| Lower extremity DVT | Vascular disorders |
|
| Nosocomial pneumonia | Respiratory, thoracic and mediastinal disorders |
|
| Agitation/delirium | Psychiatric disorders |
|
| Hypotension | Vascular disorders |
|
| A Fib | Cardiac disorders |
|
| Apnea/desaturation during weaning | Respiratory, thoracic and mediastinal disorders |
|
| Sedation interruption associated with desaturation and tachycardia | Respiratory, thoracic and mediastinal disorders |
|
| Failure to wean from ventilator | Respiratory, thoracic and mediastinal disorders |
|
| Anemia | Blood and lymphatic system disorders |
|
| Gastritis | Gastrointestinal disorders |
|
| Azotemia | Blood and lymphatic system disorders |
|
| Urinary tract infection | Renal and urinary disorders |
|
| Chronic hyponatremia | Blood and lymphatic system disorders |
|
| Gastric and duodenal ulcers | Gastrointestinal disorders |
|
| Polymicrobial bilateral pneumonia | Respiratory, thoracic and mediastinal disorders |
|
| Hepatic encephalopathy | Hepatobiliary disorders |
|
| Sepsis | Infections and infestations |
|
| Lower GI bleed | Gastrointestinal disorders |
|
| encephalopathy | Nervous system disorders |
|
| renal failure | Renal and urinary disorders |
|
| Myopathy | Musculoskeletal and connective tissue disorders |
|
| Clostridium difficile colitis | Infections and infestations |
|
| Pneumonia | Respiratory, thoracic and mediastinal disorders |
|
| Bacterial peritononitis | Infections and infestations |
|
| ARD'S | Respiratory, thoracic and mediastinal disorders |
|
| Extremity ischemia | Vascular disorders |
|
| Acute renal failure | Renal and urinary disorders |
|
| Pleural effusion | Respiratory, thoracic and mediastinal disorders |
|
| IVC | Vascular disorders |
|
| Dehydration | Metabolism and nutrition disorders |
|
| VATS/Empyema | Surgical and medical procedures |
|
| Sacral decubitus | Skin and subcutaneous tissue disorders |
|
| DVT | Vascular disorders |
|
| Depression | Psychiatric disorders |
|
Not provided
Not provided
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |